AstraZeneca and Daiichi Sankyo have reported that their latest antibody-drug conjugate, Datroway, significantly improves survival outcomes for patients with triple-negative, metastatic breast cancer—one of the most aggressive and treatment-resistant forms of the disease.
In the pivotal Phase 3 TROPION-Breast02 trial involving nearly 650 patients unable to benefit from immunotherapy, Datroway extended median overall survival to 23.7 months compared to 18.7 months for those receiving standard chemotherapy. Participants treated with Datroway also experienced a much longer median progression-free survival at 10.8 months versus 5.6 months with chemotherapy, alongside a higher tumor response rate (63% vs. 29%). The trial not only met its primary goal of reducing the risk of disease progression or death by 43%, but also demonstrated a lower incidence of treatment discontinuation, as patients remained on therapy twice as long as those on chemotherapy.
Datroway targets the TROP2 protein, which is highly expressed in multiple cancers. The drug’s precision allows effective delivery of chemotherapy directly to tumors while sparing healthy cells, reducing side effects and improving tolerability. AstraZeneca expects Datroway’s success will expand treatment choices for patients facing poor prognoses and limited options, with further regulatory approvals anticipated in new global markets.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!